News and features

A combination of two existing skin cancer drugs and a third experimental drug could lead to a new strategy for treating patients who do not respond to existing therapies, a new study in mice suggests.

New adaptive radiotherapy technique for head and neck cancer can deliver a more robust treatment plan in a shorter timeframe on MR Linac, compared with the current method used by most radiotherapy centres.

Infertile men may be twice as likely to develop breast cancer than those without fertility issues, according to new research published today.

To mark our outstanding success in REF2021, Gege Li spoke to two of our researchers here at the ICR who have played central roles in improving the use of radiotherapy in the treatment of breast cancer – transforming the lives of many thousands of patients.

To mark our outstanding success in REF2021, Gege Li spoke to several of our researchers here at the ICR who have pioneered improved use of radiotherapy in the treatment of prostate cancer.

To mark our outstanding success in REF2021, Alison Halliday spoke to several of our researchers here at the ICR who were instrumental in the development of PARP inhibitors, a type of targeted drug that’s been approved for use in breast, ovarian and prostate cancer.

To mark our outstanding success in REF2021, Alison Halliday shares the story of how our researchers revealed the 3D structure of the key cancer protein AKT, catalysing the discovery and development of at least 12 drugs now in clinical trials for a variety of cancers.

The Institute of Cancer Research, London, has rated second in REF 2021 – the Government’s evaluation of university research quality – among all higher education institutions in the UK that submitted at least two units of assessment.

Professor Kristian Helin, Chief Executive and President at The Institute of Cancer Research, London, and Professor Trevor Graham, Director of the ICR’s Centre for Evolution and Cancer, have been awarded prestigious Fellowships for the Academy of Medical Sciences (AMS).

The ICR is saddened to learn of the death of Dr Mike Ormerod, who headed the ICR’s flow cytometry facility in Sutton in the 1980s.

Scientists have found a genetic mutation that results in cancer cells being able to tolerate having an abnormal number of chromosomes – a condition which normally kills cells – allowing them to adapt to their environment and continue to grow.

Pancreatic cancers recycle resources to fuel their survival and growth, opening up the possibility of new treatments aimed at stopping them from doing so, scientists report.